Tulobuterol transdermal patch - Sparsha Pharma
Latest Information Update: 23 Jul 2015
At a glance
- Originator Sparsha Pharma
- Class Antiasthmatics; Bronchodilators
- Mechanism of Action Beta 2 adrenergic receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Asthma; Chronic obstructive pulmonary disease